Strides Pharma, Ennaid Therapeutics partner to produce life saving oral covid tablet

Bengaluru: Strides Pharma Science Limited has recently announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with Ennaid Therapeutics, to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.

Ennaid's partnership with discovery scientists at Universidad Católica de Murcia (UCAM), identified a therapeutic target to treat COVID‐19 using artificial intelligence drug discovery platforms. Initial tests show antiviral activity effective against SARS CoV‐2, the virus that causes COVID‐19, by inhibiting 90% of the virus' replication in vitro studies. These results are so compelling that Ennaid is ready to seek emergency authorization from the FDA in the United States as well an approval for compassionate use in India.

Strides will be the exclusive manufacturing partner to Ennaid for the product.

Ennaid's CEO, Darnisha Harrison, commented on the impact of the epidemic and partnership with Strides: "The magnitude of human loss in India due to COVID‐19 compelled Ennaid India Private Limited to partner with Strides Pharma extending critical resources to aid its government. We are honored to join forces with an India‐based company to bring hope and healing at a time when it's critically needed. Since the drug was previously approved by the FDA for other indication, it has already been proven safe in humans. What we have will not only bring much needed relief to India but to patients around the world. With more than 30 million people infected with COVID‐19 in America and over 100 million in the world, a drug that treats mild to moderate symptoms and helps block replication of the virus is a top priority"